Skip to Main Content

Paper Details

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Blood advances
8
2023
CAR-T, CAR-T cell products, Patients, RRMM, T, T-cell, chimeric antigen receptor, chimeric antigen receptor (CAR)-T cells, myeloma, patients, refractory multiple myeloma, relapsed
Author NameAffiliation
Erin MoshierTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Sundar JagannathTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 2

Datasets

Release 1.2